Golden Helix Inc., a leading bioinformatics solutions provider, has now announced the integration of MedGenome's OncoMD into their VarSeq software. The integration will provide VarSeq users with the option to access over 2 million annotated cancer variants.
OncoMD is a comprehensive knowledge base of cancer-specific genetic alterations captured from peer-reviewed scientific publications by a team of biomedical curators. After filtering variants of interest using VarSeq, customers can quickly prioritize actionable variants using OncoMD and make clinical decisions based on sensitivity of variants to approved drugs and enrollment to open clinical trials.
VarSeq software streamlines the process of annotating and filtering variants obtained from NGS pipelines, allowing both research scientists and clinicians to find variants of interest in a very efficient and straightforward manner. It simplifies the user interface and provides a scalable architecture featuring repeatable workflows, note taking, reporting, and filter parameter prototyping.
"This is an exciting partnership with Golden Helix to be able to deliver a robust medical informatics solution that enables precision medicine in the global clinical market," said Sam Santhosh, chief executive officer, MedGenome.
"Providing VarSeq users with access to OncoMD, allows clinicians to better tailor diagnostic and therapeutic strategies to individual patients. "Having key insights to cancer hotspots and known drug sensitivities, essentially moves precision medicine forward,” said Andreas Scherer, president and chief executive officer, Golden Helix.